Detection of neutralizing interleukin-17 antibodies in autoimmune polyendocrinopathy syndrome-1 (APS-1) patients using a novel non-cell based electrochemiluminescence assay

Cytokine

Volumn 50, Issue 2, 2010, Pages 129-137

  Cludts, Isabelle ^a   Meager, Anthony ^a   Thorpe, Robin ^a   Wadhwa, Meenu ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Cell based assays; Competitive ligand binding assay; Electrochemiluminescence assay; Interleukin 17A (IL 17A); Neutralizing antibodies

Indexed keywords

AUTOANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 17 RECEPTOR; REAGENT;

ANTIBODY DETECTION; ANTIBODY SCREENING; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE POLYENDOCRINOPATHY SYNDROME 1; BLOOD SAMPLING; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOGENICITY; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN BINDING; RELIABILITY; THYMOMA;

ANTIBODIES, NEUTRALIZING; BINDING, COMPETITIVE; CHEMILUMINESCENT MEASUREMENTS; ELECTROCHEMICAL TECHNIQUES; HUMANS; IMMUNOASSAY; INTERLEUKIN-17; LIGANDS; POLYENDOCRINOPATHIES, AUTOIMMUNE; STREPTAVIDIN; SYNDROME;

EID: 77950864580     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.01.001     Document Type: Article

References (29)

1. Yao Z., Painter S.L., Fanslow W.C., Ullrich D., Macduff B.M., Spriggs M.K., et al. Cutting edge: human IL-17: a novel cytokine derived from T cells. J Immunol 1995, 155:5483-5486.
2. Aggarwal S., Gurney A.L. IL-17: a prototype member of an emerging family. J Leukoc Biol 2002, 71:1-8.
3. Gaffen S.L. An overview of IL-17 function and signalling. Cytokine 2008, 43:402-407.
4. Ouyang W., Kolls J.K., Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467.
5. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593-2603.
6. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis. Cytokine 2008, 41:84-91.
7. Lowes M.A., Bowcock A.M., Kreuger J.G. Pathogenesis and therapy of psoriasis. Nature 2007, 445:866-873.
8. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
9. Wright J.F., Bennett F., Li B., Brooks J., Luxenberg D.P., Whitters M.J., et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA.IL-17RC receptor complex. J Immunol 2008, 181:2799-2805.
10. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2006, 91:2843-2850.
11. Wolff A.S., Erichsen M.M., Meager A., Magitta N.F., Myhre A.G., Bollerslev J., et al. Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J Clin Endocrinol Metab 2007, 92:595-603.
12. Alimohammadi M., Dubois N., Sköldberg F., Hallgren A., Tardivel I., Hedstrand H., et al. Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen. Proc Natl Acad Sci USA 2009, 106:4396-4401.
13. Meager A., Visvalingam K., Peterson P., Möll K., Murumägi A., Krohn K., et al. Anti-interferon autoantibodies in autoimmune polyendocrine syndrome type 1. PLoS Med 2006, 3(7):e289.
14. Meloni A., Furcas M., Cetani F., Marcocci C., Falorni A., Perniola R., et al. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab 2008, 93:4389-4397.
15. Meager A. Biological assays for interferons. J Immunol Methods 2002, 261:21-26.
16. Meager A. Measurement of cytokines by bioassays: theory and application. Methods 2006, 38:237-252.
17. Moore M., Meager A., Wadhwa M., Burns C. Measurement of neutralising antibodies to type I interferons by gene expression assays specific for type 1 interferon-inducible 6-16 mRNA. J Pharm Biomed Anal 2009, 49:534-539.
18. Lallemand C., Meritet J.-F., Erickson R., Grossberg S.E., Roullet E., Lyon-Caen O., et al. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene. J Interferon Cytokine Res 2008, 28:393-404.
19. Oftedal B., Bøe Wolff A.S., Bratland E., Kämpe O., Perheentupa J., Myhre A.G., et al. Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clin Immunol 2008, 129:163-169.
20. Zhang L., Barker J.M., Babu S., Su M., Stenerson M., Cheng M., et al. A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1. Clin Immunol 2007, 125:131-137.
21. Moxness M., Tatarewicz S., Weeraratne D., Murakami N., Wullner D., Mytych D., et al. Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin. Chem. 2005, 51:1983-1985.
22. Kobrynski L., Tanimune L., Pawlowski N.A., Douglas S.D., Campbell D.E. A comparison of electrochemiluminescence and flow cytometry for the detection of natural latex-specific human immunoglobulin E. Clin Diagn Lab Immunol 1996, 3:42-46.
23. Liang M., Klakamp S.L., Funelas C., Lu H., Lam B., Herl C., Umble A., et al. Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms. Assay Drug Dev Technol 2007, 5:655-662.
24. Loyet K.M., Deng R., Liang W.-C., Wu Y., Lowman H.B., DeForge L.E. Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study. J Immunol Methods 2009, 345:17-28.
25. Hu J., Gupta S., Swanson S.J., Zhuang Y. A bioactive drug quantitation based approach for the detection of anti-drug neutralizing antibodies in human serum. J Immunol Methods 2009, 345:70-79.
26. Wadhwa M., Thorpe R. Strategies, assays for the assessment of unwanted immunogenicity. J Immunotoxicol 2006, 3:115-121.
27. Gross J., Moller R., Henke W., Hoesel W. Detection of anti-EPO antibodies in human sera by a bridging ELISA is much more sensitive when coating biotinylated rhEPO to streptavidin rather than using direct coating of rhEPO. J Immunol Methods 2006, 313:176-182.
28. Gupta S., Indelicato S.R., Jethwa V., Kawabata T., Kelley M., Mire-Sluis A.R., et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 2007, 321:1-18.
29. European Medicines Agency. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins: 2007. Available at: http://www.emea.europa.eu/pdfs/human/biosimilar/1432706en.pdf.